Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019.
There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan.
However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.
Company Details
- Employees
- 12
- Founded
- 2019
- Address
- 46-29 Yoshidashimoadachi-Cho, Sakyo-Ku, Med-Pharm Collaboration Bldg. Kyoto University,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.regenephro.co.jp/en
- Keywords
- 藤沢市.
- HQ
- Kyoto, Kyoto
Rege Nephro Co., Ltd. Questions
Rege Nephro Co., Ltd.'s website is https://www.regenephro.co.jp/en
Rege Nephro Co., Ltd.'s LinkedIn profile is https://jp.linkedin.com/company/rege-nephro
Rege Nephro Co., Ltd. has
12 employees.
View email and phone details for 12
employees at Rege Nephro Co., Ltd..
Rege Nephro Co., Ltd.'s industry is
Biotechnology Research
Rege Nephro Co., Ltd.'s top competitors are
Syntheticgestalt,
Les Uniques,
Luca Science Inc.,
Plimes Inc.,
Genoplan Asia Pacific,
Plusman Llc,
Shonan Health Innovation Park,
Alt.lab,
Cosomil, Inc.,
Nxi Therapeutics Ag.
Rege Nephro Co., Ltd.'s categories are Biotechnology Research
Rege Nephro Co., Ltd.'s founding year is 2019
